Clinical trials: Sirolimus
Hypertension
Pharmacokinetics of Sirolimus and Tacrolimus in Liver Transplant Recipients With Tacrolimus Toxicity
Pharmacokinetics of Tacrolimus and Sirolimus alone and in combination in liver transplant recipients.
- Trial name
- Sirolimus (NCT01709136)
- Testing
- Sirolimus
- Volunteers
- 3 people
- Sponsor
- University of Pittsburgh
Lymphangioleiomyomatosis, Tuberous Sclerosis Complex
Feasibility of [11C]Acetate-PET in LAM and TSC
This study aims to assess [11C]acetate positron emission tomography (PET)/computed tomography (CT) as a biomarker for renal angiomyolipomas and pulmonary lymphangioleiomyomatosis (LAM) and an early biomarker of response to…
- Trial name
- NCT05467397
- Testing
- [11C]acetate
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Brigham and Women's Hospital
Squamous Cell Skin Carcinoma
Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma
Solid organ transplant recipients (SOTR) have a 3-5x increased occurrence of cancer in contrast to the general population with basal and squamous cell skin cancer.
- Trial name
- NCT01764607
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Florida
Metastatic Breast Cancer
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
Phase I: will look at different dose levels and regimens of everolimus combined with weekly trastuzumab and paclitaxel therapy in patients with HER-2 overexpressing metastatic breast cancer.
- Trial name
- NCT00426556
- Testing
- Everolimus, Trastuzumab, Paclitaxel
- Where
- 20 sites in United States, Belgium and 3 more
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
Brain Tumor, Glioblastoma
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and best schedule of the combination of everolimus and sorafenib that can be given to patients with malignant glioma.
- Conditions
- Brain Tumor, Glioblastoma, Anaplastic Glioma
- Trial name
- NCT01434602
- Testing
- everolimus, sorafenib
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Transplantation, Kidney Disease
Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults
Transplant rejection occurs when a patient's body does not recognize the new organ and attacks it. Patients who have kidney transplants must take drugs to prevent transplant rejection.
- Trial name
- NCT00078559
- Testing
- Alemtuzumab, Sirolimus, Tacrolimus
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Wisconsin, Madison
Ischemic Heart Disease
Randomized Study Comparing Endeavor With Cypher Stents (PROTECT)
The PROTECT TRIAL is a randomized stent trial with 8800 patients in approximately 200 hospitals, which is designed to evaluate whether the Endeavor stent PROTECTS against late stent thrombosis resulting in less deaths and…
- Trial name
- PROTECT (NCT00476957)
- Testing
- Stent
- Where
- Netherlands
- Volunteers
- 8,709 people
- Sponsor
- Medtronic Vascular
Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma
Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative
This phase II trial studies how well pegylated liposomal doxorubicin, bevacizumab, and everolimus work in treating patients with triple-negative breast cancer with tumors predicted insensitive to standard chemotherapy.
- Trial name
- NCT02456857
- Testing
- Bevacizumab, Everolimus, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer, Fallopian Tube Cancer
Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer
This study will investigate the efficacy as well as the safety of RAD001 in combination with bevacizumab for recurrent ovarian, peritoneal, and fallopian tube cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- RADBEV (NCT01031381)
- Testing
- RAD001, bevacizumab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Pittsburgh
Prostate Cancer
Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT01083368
- Testing
- temsirolimus, bevacizumab, polymorphism analysis
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Case Comprehensive Cancer Center
Chronic Granulomatous Disease
Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide
Background: Chronic Granulomatous Disease (CGD) causes immune system problems. Treatment is usually a bone marrow transplant from a fully matched donor.
- Trial name
- NCT02282904
- Testing
- Sirolimus, Donor peripheral blood stem cells., Cyclophosphamide post transplant
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Castleman Disease, Castleman's Disease, Multicentric
Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease
The purpose of this study is to understand the impact of sirolimus on idiopathic multicentric Castleman disease.
- Trial name
- NCT03933904
- Testing
- Sirolimus
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Pennsylvania
Renal Cell Carcinoma
Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma
This study assessed the efficacy and safety of first-line RAD001 followed by second-line sunitinib versus the opposite sequence: first-line sunitinib followed by second-line RAD001 for the treatment of patients with MRCC.
- Trial name
- RECORD-3 (NCT00903175)
- Testing
- everolimus, sunitinib
- Where
- 84 sites in United States, Argentina and 17 more
- Volunteers
- 471 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplant Failure and Rejection
A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression
This is an open label, single-center, randomized phase IV pilot study of steroid and calcineurin inhibitor avoidance in renal transplant recipients.
- Trial name
- Cell220 (NCT00166712)
- Testing
- Tacrolimus (TAC), Sirolimus, Alemtuzumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Northwestern University
Carcinoma, Renal Cell, Lymphoma, Mantle-Cell
INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus
The principal objective of the study is to evaluate the efficacy and safety of temsirolimus use in patients with Renal Cell Carcinoma and Mantle Cell Lymphoma.
- Trial name
- NCT01367457
- Testing
- Temsirolimus (Non-Interventional Study)
- Where
- 16 sites in Spain
- Volunteers
- 243 people
- Sponsor
- Pfizer
Male Breast Carcinoma, Recurrent Breast Carcinoma
Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
This phase I/II trial is studying the side effects and best dose of cixutumumab when given together with temsirolimus and to see how well they work in treating patients with breast cancer that has recurred (come back) at or near…
- Conditions
- Male Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT00699491
- Testing
- Cixutumumab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 192 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant
Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients
The purpose of this study is to determine if everolimus combined with reduced exposure CNI (TAC) is efficacious and safe and will support corticosteroid elimination compared to a standard exposure CNI (TAC) + MMF + steroid…
- Trial name
- NCT01544491
- Testing
- RAD001, MMF
- Where
- 31 sites in United States, Argentina and 11 more
- Volunteers
- 106 people
- Sponsor
- Novartis Pharmaceuticals
Renal Transplant Recipients
Research Study of ATG and Rituximab in Renal Transplantation
The purpose of this study is see if a combination of two drugs, (ATG and rituximab), given at the time of the transplant surgery, will help reduce or eliminate the need for long term immunosuppressive medication.
- Trial name
- RESTARRT (NCT01318915)
- Testing
- ATG, Rituximab, Tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
This phase II trial is studying the side effects and how well temsirolimus works in treating patients with refractory or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
- Trial name
- NCT00429793
- Testing
- temsirolimus
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Endometrial Carcinoma
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
This phase II trial is studying the side effects of giving bevacizumab together with temsirolimus and to see how well it works in treating patients with recurrent or persistent endometrial cancer.
- Trial name
- NCT00723255
- Testing
- bevacizumab, temsirolimus
- Where
- 41 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)